missing translation for 'onlineSavingsMsg'
Learn More
Learn More
Invitrogen™ LRRTM2 Polyclonal Antibody

Sheep Polyclonal Antibody
Brand: Invitrogen™ PA5149033
This item is not returnable.
View return policy
Description
Reconstitute at 0.2 mg/mL in sterile PBS.
The Leucine-rich repeat transmembrane neuronal proteins (LRRTMs) are differentially expressed in the nervous system and were recently found to instruct presynaptic and mediate postsynaptic glutamatergic differentiation, with LRRTM1 and LRRTM2 most potent at inducing presynaptic differentiation. Each LRRTM protein is a type I transmembrane containing ten extracellular leucine-rich repeats and a short intracellular tail and has a developmentally regulated pattern distinct from all others. LRRTM2 interacts with PSD-95 and regulates the surface expression of AMPA receptors. LRRTM2 also functions as a neurexin ligand, binding both Neurexin 1-alpha and -beta, suggesting that LRRTM2-Neurexin1 interaction plays a critical role in regulatory excitatory synapse development.
Specifications
| LRRTM2 | |
| Polyclonal | |
| Unconjugated | |
| LRRTM2 | |
| AI851755; BB129880; C630011A14Rik; KIAA0416; leucine rich repeat transmembrane neuronal 2; leucine-rich repeat neuronal 2 protein; leucine-rich repeat transmembrane neuronal 2 protein; leucine-rich repeat transmembrane neuronal protein 2; LRRN2; LRRTM2; mKIAA0416 | |
| Sheep | |
| Antigen affinity chromatography | |
| RUO | |
| 107065, 26045 | |
| Store at 4°C short term. For long term storage, store at -20°C, avoiding freeze/thaw cycles. | |
| Lyophilized |
| Immunohistochemistry (Frozen), Western Blot | |
| 0.2 mg/mL | |
| PBS with 5% trehalose and no preservative | |
| O43300, Q8BGA3 | |
| LRRTM2 | |
| Mouse myeloma cell line NS0-derived recombinant human LRRTM2, Cys34-Arg422. | |
| 100 μg | |
| Primary | |
| Human, Mouse | |
| Antibody | |
| IgG |
Product Content Correction
Your input is important to us. Please complete this form to provide feedback related to the content on this product.
Product Title
Spot an opportunity for improvement?Share a Content Correction